Company intelligence / Profile preview

Metavention

Maple Grove, Minnesota, United Statesmetavention.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

The iRF Denervation System has completed U.S. feasibility study enrollment for hepatic denervation in patients with metabolic syndrome, including type 2 diabetes and hypertension. The study aims to demonstrate safety and potential efficacy for improving glycemic control and blood pressure via a single minimally invasive procedure targeting overactive sympathetic nerves. No pivotal or late-stage results have been reported publicly.

Therapeutic areas: Metabolic DisordersCardiovascularEndocrinology
Modalities: DeviceRadio frequency ablation (catheter-based)
Industry: Therapeutic Medical Devices

Partnerships

none disclosed as of June2025

Beyond the preview

Go deeper on Metavention.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metavention.

Explore the full profile